Flip Flop: ED Drugs Not Tied to Prostate Cancer ReturnFlip Flop: ED Drugs Not Tied to Prostate Cancer Return

Erectile dysfunction (ED) is a common adverse effect of prostate cancer therapy. But is the use of these drugs tied to biochemical recurrence? New evidence counters an earlier study. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Related Links:

(European Association of Urology) Scientists have found that men with high neuroticism -- between a quarter and a fifth of men in developed countries -- are significantly more likely to suffer from adverse events such as erectile dysfunction and incontinence, which may put their recovery from prostate cancer surgery at risk. The researchers say that this means cancer teams may need to consider testing for personality types to try to ensure that patients being treated for prostate cancer receive the best care.
Source: EurekAlert! - Social and Behavioral Science - Category: International Medicine & Public Health Source Type: news
CONCLUSION: CaP patients who sustain higher BL during RP showed worse functional outcomes. High BL during ORP or RALP represented an independent predictor of erectile dysfunction and incontinence after surgery. However, the effect of high BL on the continence was temporarily and not present at 1 year after surgery in ORP and after 3 months in RALP. PMID: 30857988 [PubMed - as supplied by publisher]
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
AbstractRadical prostatectomy, the preferred treatment option for organ-confined prostate cancer, is associated with a wide variety of sexual dysfunctions including erectile and orgasmic dysfunctions. Climacturia is a type of orgasmic dysfunction that has been reported to occur in 20 –60% of men after radical prostatectomy. Several treatment strategies for climacturia have been evaluated and recommended including behavioral changes, use of special devices, medications, specialized therapies, and surgeries. Inflatable penile prosthesis implantation might be the treatment of cho ice when conservative management approac...
Source: Current Urology Reports - Category: Urology & Nephrology Source Type: research
Condition:   Low Risk Prostate Cancer Intervention:   Drug: TOOKAD VTP Sponsors:   Steba Biotech S.A.;   International Drug Development Institute;   PrimeVigilance LTD Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION: The most predictive factor of 3yED was the dose to the PB. This may be explained by variation in individual patients' anatomy and this could allow for the development of better strategies to prevent ED. PMID: 30761939 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Publication date: Available online 13 February 2019Source: Actas Urológicas Españolas (English Edition)Author(s): J. Muñoz-Rodríguez, N. Hannaoui, A. Domínguez, C. Centeno, V. Parejo, M.A. Rosado, J. Prats, S. NavarroAbstractIntroductionGiven the high prevalence of erectile dysfunction in male population between 40 and 70 years old and the effect of radical prostatectomy on this domain, it is important to perform a baseline study.Material and methodsPrior radical prostatectomy, erectile function has been assessed prospectively in 112 prostate cancer patients using the erectile function (E...
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
CONCLUSIONS: Gay prostate cancer survivors' narratives about sexual changes circle around similar bodily changes as heterosexual men's, such as erectile problems and weaker orgasms. The loss of ejaculate was experienced as more debilitating for gay men. Men who had anal sex were concerned about penetration difficulties as well as sensations of anal stimulation. Additional studies are required to better understand the role of the prostate among a diversity of men, regardless of sexuality. PMID: 30727809 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
Condition:   Prostate Cancer Interventions:   Radiation: Radiation by brachytherapy;   Radiation: Radiation by SBRT Sponsor:   Center Eugene Marquis Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Erectile Dysfunction, CTCAE;   Impotence;   Prostate Adenocarcinoma Interventions:   Drug: Atorvastatin;   Drug: Pentoxifylline;   Dietary Supplement: Vitamin E Compound Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Prostate Cancer Interventions:   Radiation: Radiation by brachytherapy;   Radiation: Radiation by SBRT Sponsor:   Center Eugene Marquis Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer Therapy | Erectile Dysfunction | Hematology | Prostate Cancer | Study